Business Wire

Exclusive Networks Grows X-OD Reach to 9 European Markets to Introduce Complete Fortinet Security Fabric Portfolio on a Subscription Basis

22.2.2021 12:00:00 EET | Business Wire | Press release

Share

Exclusive Networks today unveiled the latest evolution of its X-OD platform with expansion into Germany, Spain, Belgium, Finland, Austria and Ireland. This coincides with the introduction of Fortinet to the X-OD portfolio offering, with the end-to-end availability of all Fortinet solutions through the Fortinet Security Fabric on a subscription basis – a unique channel proposition in global distribution.

X-OD is now available to partners in 9 European markets (France, UK and the Netherlands already launched) with aggressive plans to extend into all global regions later this year. Exclusive Networks is growing its subscription revenues 5x faster than traditional capex-based sales, with X-OD a significant driver in the acceleration of market evolution.

“Wherever we go with X-OD, it is growing fast – now in the Nordics, Iberia and DACH, and across Benelux, UK&I and France,” said Jesper Trolle, CEO of Exclusive Networks. “The global pandemic has undoubtedly accelerated digital transformation more generally, making this proposition even more relevant to business needs. Digital customer experience, big data insights and opex-based consumption are here to stay. And our roadmap is on track to extend the capabilities of X-OD beyond Europe and into every Exclusive operating territory.”

The enhanced opportunities made possible by X-OD are particularly relevant when it comes to key technologies such as SD-WAN and market segments such as MSSP. Customer organisations face the challenge of shifting from predominantly opex-based MPLS investments into a large-scale, capex-based network evolution to SD-WAN infrastructure. These issues are negated and opportunities unlocked by X-OD-enabled consumption models.

In the case of MSSP partners who ordinarily face investing upfront in the infrastructure capabilities to drive their own managed security services, X-OD enables them to buy technology in the same way they sell it. The sheer breadth, diversity of complementary nature of Fortinet’s portfolio also benefits from X-OD’s ability to ‘subscriptionise’ products and services into discreet packages, and even allow partners to bundle these with their own service wraps that are elegantly presented to customers as a single, easy-to-consume offering. Partners benefit yet further from X-OD’s fully digital customer experience and access to rich data insights that fuel upsell/cross-sell initiatives and targeted sales campaigns.

“Fortinet’s partnership with Exclusive Networks is geared to create exceptional value and opportunity for our partners and customers,” said Patrice Perche, Chief Revenue Officer & EVP Support at Fortinet. “With X-OD, Exclusive has engineered another genuinely innovative contribution to channel dynamics that aligns with how we see the world and how we want our partners to be enabled and supported. This represents significant benefits to all levels of our partner community, and ultimately provides our customers with new ways of consuming our market-defining products and services.”

“We see fantastic opportunities for the vendors who have committed to X-OD, and are very excited to introduce Fortinet and its extensive portfolio of solutions in these early stages of worldwide rollout,” added Jesper Trolle. “We are aligned with theirs and our other vendor partners’ visions for innovation, recurring revenue and market flexibility. Together we are empowering channel partners to make a fast, safe and simple transition to subscription-based consumption both for their customers and their own business models, allowing them to sell ‘everything as a service’.”

About X-OD

X-OD is an on-demand platform that brings together and enhances all of Exclusive Networks’ products and services in one, user-friendly place. The platform is the centre of a new digitalised technology distribution ecosystem that is connecting the full value chain, bringing vendors and resellers closer to their customers.

X-OD is pivotal in enabling the shift to the subscription business model. The platform is transforming capex to opex payments, enabling technology to be bought in the same way it is sold and consumed. It is this flexibility combined with on-demand functionality, speed and simplicity that makes X-OD so relevant in a ‘customer-first’ world. www.x-od.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jemma Lowman
exclusivegroup@wearecohesive.com
01291626200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye